Table 3: Crude and adjusted relative risks (95% CIs) for the associations between in utero exposure to atropinic drugs and the use of drugs for digestive disorders

		Number	Univariate analysis		Multivariate analysis	
		of children*	RR [IC] _{95%}	р	RR _a [IC] _{95%}	p
In utero exposure to	No exposure	5,711	1	<.0001	1	<.0001
atropinic drugs	Exposure	2,644	1.27 [1.22; 1.32]		1.11 [1.06; 1.16] ^a	
	0	5,711	1	<.0001	1	0.0003
Atropinic burden in	[1-3[1,381	1.22 [1.16; 1.29]		1.10 [1.03; 1.17] ^b	
utero	[3-9[1,149	1.29 [1.22 ; 1.36]		1.11 [1.05; 1.19] ^b	
	≥9	114	1.54 [1.34 ; 1.77]		1.22 [1.02; 1.45] ^b	
Number of dates on which atropinic	0	5,711	1	<.0001	1	<.0001
	1	1,757	1.21 [1.15; 1.27]		1.09 [1.03; 1.15] ^c	
drugs were dispensed	2	518	1.34 [1.24 ; 1.44]		1.14 [1.05; 1.24] ^c	
urugs were uispenseu	≥3	369	1.44 [1.33 ; 1.57]		1.18 [1.07; 1.31] ^c	

^{*} Women with missing values for variables taken into account in the adjustment were excluded

^a Adjusted on parity, number of drugs dispensed to the mother during pregnancy, gender of the child, breastfeding, major congenital anomaly and metabolic disease.

^b Adjusted on parity, number of drugs dispensed to the mother during pregnancy, gender of the child, breastfeeding and major congenital anomaly.

^c Adjusted on parity, number of drugs dispensed to the mother during pregnancy, gender of the child, breastfeding, major congenital anomaly and metabolic disease.